BillionToOne, Inc. BLLN Prenatal — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BillionToOne, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BillionToOne, Inc. 's prenatal — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BillionToOne, Inc. 's prenatal — revenue?
- BillionToOne, Inc. (BLLN) reported prenatal — revenue of $96.53M in Q1 2026.
- How has BillionToOne, Inc. 's prenatal — revenue changed year-over-year?
- BillionToOne, Inc. 's prenatal — revenue increased by 72.1% year-over-year, from $56.08M to $96.53M.
- What does prenatal — revenue mean?
- This metric represents the total gross sales generated from the company's prenatal molecular diagnostic testing services. It reflects the market adoption and commercial performance of non-invasive screening products designed to assess fetal genetic health from maternal blood samples. This revenue stream is a primary indicator of the company's ability to scale its precision diagnostics platform within the reproductive health market.